Li-Mei Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li-Mei Han has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bailing Zhang
Department of Computer Science and Software Engineering, Xi’an Jiaotong-Liverpool University, SIP, Suzhou 215123, China
1 shared publication - Chun Wang
Department of Clinical Laboratory, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
1 shared publication Du-Xian Liu
Department of pathology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China
1 shared publicationGong-Ting Wang
Key Laboratory of Resources Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an, China
1 shared publication- Hui Dong
Institute of Frontier and Interdisciplinary Science Key Laboratory of Particle Physics and Particle Irradiation (MOE) Shandong University 266237 Qingdao Shandong China
1 shared publication - Hui Li
Department of Respiratory and Critical Care Medicine, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, P.R. China
1 shared publication
Latest Publications
- 28 May 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (2) , 107220
Phage therapy combats pan drug-resistant Acinetobacter baumannii infection safely and efficiently
- 28 May 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (2) , 107220
Phage therapy combats pan drug-resistant Acinetobacter baumannii infection safely and efficiently
- 1 August 2022
- Published by American Scientific Publishers in Journal of Biomaterials and Tissue Engineering
- Vol. 12 (8) , 1525-1529
miR-144-3p Derived from Bone Marrow Mesenchymal Stem Cells (BMSCs) Restrains the Drug Resistance of Acute Myeloid Leukemia (AML)
This study assessed whether miR-144-3p derived from BMSCs restrains the drug resistance of AML. Our study intends to assess miR-144-3p’s role in AML drug resistance. Drug resistance AML cells were transfected with miR-144-3p mimic or NC followed by measuring miR-144-3p level, relation of miR-144-3p with Wnt, cell activity and apoptosis by flow cytometry and the expression of signal proteins by Western Blot. The action of miR-144-3p in inducting drug resistance of K562/AND was more effective. Cell apoptosis and proliferative index was increased by overexpression of miR-144-3p along with significantly down regulated Wnt. In conclusion, the malignant invasion of AML with drug resistance is increased by miR-144-3p derived from BMSCs through regulating the Wnt/β-catenin signal, indicating that miT-144-3p might be a new target for the treatment of AML.
- 1 August 2022
- Published by American Scientific Publishers in Journal of Biomaterials and Tissue Engineering
- Vol. 12 (8) , 1525-1529
miR-144-3p Derived from Bone Marrow Mesenchymal Stem Cells (BMSCs) Restrains the Drug Resistance of Acute Myeloid Leukemia (AML)
This study assessed whether miR-144-3p derived from BMSCs restrains the drug resistance of AML. Our study intends to assess miR-144-3p’s role in AML drug resistance. Drug resistance AML cells were transfected with miR-144-3p mimic or NC followed by measuring miR-144-3p level, relation of miR-144-3p with Wnt, cell activity and apoptosis by flow cytometry and the expression of signal proteins by Western Blot. The action of miR-144-3p in inducting drug resistance of K562/AND was more effective. Cell apoptosis and proliferative index was increased by overexpression of miR-144-3p along with significantly down regulated Wnt. In conclusion, the malignant invasion of AML with drug resistance is increased by miR-144-3p derived from BMSCs through regulating the Wnt/β-catenin signal, indicating that miT-144-3p might be a new target for the treatment of AML.